What is he best known for?
The fields of study he is best known for:
His scientific interests lie mostly in Mycobacterium tuberculosis, Tuberculosis, Drug resistance, Molecular epidemiology and Microbiology.
Leen Rigouts frequently studies issues relating to Rifampicin and Mycobacterium tuberculosis.
He combines subjects such as Internal medicine, Natural history, Pharmacology and Family medicine with his study of Tuberculosis.
The Drug resistance study which covers rpoB that intersects with Gold standard.
His Molecular epidemiology study combines topics in areas such as Ecology, Mycobacterium bovis and Chromosomal region, Locus.
His Microbiology research is multidisciplinary, incorporating perspectives in Polymerase chain reaction and Mycobacterium, Bacteria.
His most cited work include:
- Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology (899 citations)
- Molecular evidence to support a proposal to reserve the designation Mycobacterium avium subsp. avium for bird-type isolates and 'M. avium subsp. hominissuis' for the human/porcine type of M. avium. (266 citations)
- Rifampin Drug Resistance Tests for Tuberculosis: Challenging the Gold Standard (172 citations)
What are the main themes of his work throughout his whole career to date?
Leen Rigouts focuses on Mycobacterium tuberculosis, Tuberculosis, Drug resistance, Microbiology and Rifampicin.
As part of one scientific family, Leen Rigouts deals mainly with the area of Mycobacterium tuberculosis, narrowing it down to issues related to the Genetics, and often Mycobacterium ulcerans and Mycobacterium bovis.
The study incorporates disciplines such as Internal medicine, Multiple drug resistance, Genotype and Virology in addition to Tuberculosis.
He interconnects Mutation, Antibiotics, Capreomycin and Anti tuberculosis in the investigation of issues within Drug resistance.
In his research, 16S ribosomal RNA is intimately related to Mycobacterium, which falls under the overarching field of Microbiology.
Leen Rigouts has researched Rifampicin in several fields, including Antibacterial agent, Pediatrics and Isoniazid.
He most often published in these fields:
- Mycobacterium tuberculosis (54.93%)
- Tuberculosis (51.41%)
- Drug resistance (33.10%)
What were the highlights of his more recent work (between 2016-2021)?
- Mycobacterium tuberculosis (54.93%)
- Tuberculosis (51.41%)
- Drug resistance (33.10%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Mycobacterium tuberculosis, Tuberculosis, Drug resistance, Rifampicin and Mycobacterium tuberculosis complex.
Leen Rigouts is studying rpoB, which is a component of Mycobacterium tuberculosis.
His Sputum study, which is part of a larger body of work in Tuberculosis, is frequently linked to Transmission, bridging the gap between disciplines.
His study in Drug resistance is interdisciplinary in nature, drawing from both Lineage, Pyrazinamide and Virology.
His study in the field of Rifampicin resistant tuberculosis is also linked to topics like World health.
His Mycobacterium tuberculosis complex research is multidisciplinary, incorporating elements of Extensively drug-resistant tuberculosis and Multi-drug-resistant tuberculosis.
Between 2016 and 2021, his most popular works were:
- A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis (166 citations)
- GWAS for quantitative resistance phenotypes in Mycobacterium tuberculosis reveals resistance genes and regulatory regions. (38 citations)
- Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase (33 citations)
In his most recent research, the most cited papers focused on:
Leen Rigouts spends much of his time researching Mycobacterium tuberculosis, Drug resistance, Rifampicin, Tuberculosis and Microbiology.
His study in Ethionamide, Prothionamide and Mycobacterium tuberculosis complex is carried out as part of his studies in Mycobacterium tuberculosis.
His Drug resistance research includes themes of Pyrazinamide, Capreomycin, Moxifloxacin, Genome and Internal medicine.
In his study, Genotype is inextricably linked to rpoB, which falls within the broad field of Rifampicin.
His Tuberculosis research incorporates elements of Phenotype, Genetics, Gene and Expanded access.
His Microbiology study integrates concerns from other disciplines, such as Mycobacterium leprae, Leprosy, Repetitive Element and Mycobacterium.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
